rs775950661
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_024685.4(BBS10):βc.2119_2120delβ(p.Val707Ter) variant causes a frameshift change. The variant allele was found at a frequency of 0.000141 in 1,613,868 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ).
Frequency
Genomes: π 0.000039 ( 0 hom., cov: 32)
Exomes π: 0.00015 ( 0 hom. )
Consequence
BBS10
NM_024685.4 frameshift
NM_024685.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 6.02
Genes affected
BBS10 (HGNC:26291): (Bardet-Biedl syndrome 10) This gene is a member of the Bardet-Biedl syndrome (BBS) gene family. Bardet-Biedl syndrome is an autosomal recessive disorder characterized by progressive retinal degeneration, obesity, polydactyly, renal malformation and cognitive disability. The proteins encoded by BBS gene family members are structurally diverse and the similar phenotypes exhibited by mutations in BBS gene family members is likely due to their shared roles in cilia formation and function. Many BBS proteins localize to the basal bodies, ciliary axonemes, and pericentriolar regions of cells. BBS proteins may also be involved in intracellular trafficking via microtubule-related transport. The protein encoded by this gene is likely not a ciliary protein but rather has distant sequence homology to type II chaperonins. As a molecular chaperone, this protein may affect the folding or stability of other ciliary or basal body proteins. Inhibition of this protein's expression impairs ciliogenesis in preadipocytes. Mutations in this gene cause Bardet-Biedl syndrome type 10. [provided by RefSeq, Jan 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.0244 CDS is truncated, and there are 2 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 12-76345864-AAC-A is Pathogenic according to our data. Variant chr12-76345864-AAC-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 406221.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr12-76345864-AAC-A is described in Lovd as [Likely_pathogenic]. Variant chr12-76345864-AAC-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BBS10 | NM_024685.4 | c.2119_2120del | p.Val707Ter | frameshift_variant | 2/2 | ENST00000650064.2 | NP_078961.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BBS10 | ENST00000650064.2 | c.2119_2120del | p.Val707Ter | frameshift_variant | 2/2 | NM_024685.4 | ENSP00000497413 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152178Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
6
AN:
152178
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000637 AC: 16AN: 251218Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135786
GnomAD3 exomes
AF:
AC:
16
AN:
251218
Hom.:
AF XY:
AC XY:
8
AN XY:
135786
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000151 AC: 221AN: 1461572Hom.: 0 AF XY: 0.000135 AC XY: 98AN XY: 727082
GnomAD4 exome
AF:
AC:
221
AN:
1461572
Hom.:
AF XY:
AC XY:
98
AN XY:
727082
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152296Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74486
GnomAD4 genome
AF:
AC:
6
AN:
152296
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74486
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Bardet-Biedl syndrome 10 Pathogenic:5
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 01, 2023 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Feb 27, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | Oct 10, 2019 | This frameshifting variant in exon 2 of 2 introduces a premature stop codon and is therefore predicted to result in loss of normal protein function. While this is not anticipated to result in nonsense mediated decay, it is expected to delete the last 17 amino acids of the BBS10 protein. This variant has been previously reported as a compound heterozygous or homozygous change in patients with Bardet-Biedl Syndrome 10 (PMID: 16582908, 25982971, 22773737, 27486776, 20472660). The ClinVar database contains an entry for this variant (Variation ID: 406221). It is present in the heterozygous state in the gnomAD population database at a frequency of 0.006% (17/282614) and thus is presumed to be rare. Based on the available evidence, the c.2119_2120del (p.Val707Ter) variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 27, 2024 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 18, 2020 | - - |
Bardet-Biedl syndrome Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Feb 07, 2018 | The p.Val707X (NM_024685.3 c.2119_2120delGT) variant in BBS10 has been previousl y reported in at least one compound heterozygous and one homozygous individual w ith Bardet-Biedl syndrome (BBS) (Stoetzel 2006, Scheidecker 2015, Lindstrand 201 6). This variant has also been reported in ClinVar (Variation ID#406221) as path ogenic. It has been identified in (15/126,508) of European chromosomes by the Ge nome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs775 950661). Although this variant has been seen in the general population, its freq uency is low enough to be consistent with a recessive carrier frequency. This no nsense variant leads to a premature termination codon at position 707, which is predicted to lead to a truncated or absent protein. Biallelic loss of function o f the BBS10 gene has been associated with Bardet-Biedl syndrome (BBS). In summar y, although additional studies are required to fully establish its clinical sign ificance, the p.Val707X variant is likely pathogenic for Bardet-Biedl syndrome ( BBS) in an autosomal recessive manner based on a predicted truncating effect and its biallelic occurrence in individuals with this disease. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 10, 2024 | This sequence change creates a premature translational stop signal (p.Val707*) in the BBS10 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 17 amino acid(s) of the BBS10 protein. This variant is present in population databases (rs775950661, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with Bardet-Biedl syndrome (PMID: 20472660, 22773737, 25982971, 27486776). ClinVar contains an entry for this variant (Variation ID: 406221). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 22, 2017 | Variant summary: The BBS10 c.2119_2120delGT (p.Val707Terfs) variant results in a premature termination codon, predicted to cause a truncated or absent BBS10 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. One in silico tool predicts a damaging outcome for this variant. This variant was found in 8/121352 control chromosomes at a frequency of 0.0000659, which does not exceed the estimated maximal expected allele frequency of a pathogenic BBS10 variant (0.0013363). This variant has been reported in multiple BBS patients. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 15, 2022 | Nonsense variant in the C-terminus predicted to result in protein truncation, as the last 17 amino acids are lost, and other loss-of-function variants have been reported downstream in the Human Gene Mutation Database (HGMD); This variant is associated with the following publications: (PMID: 21157496, 31293383, 31963381, 16582908, 25982971, 30609409, 22773737, 27659767, 21209035, 27486776, 20472660, 34940782, 35112343) - |
Retinal dystrophy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Dec 09, 2017 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at